Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database

Képénékian, Vahan; Élias, Dominique; Passot, Guillaume; Mery-Lamarche, Eliane; Goèré, Diane; Delroeux, Delphine; Quénet, François; Ferron, Gwénaël; Pezet, Denis; Guilloit, Jean-Marc; Méeus, Pierre; Pocard, Marc; Béréder, Jean-Marc; Abboud, Karine; Arvieux, C.; Brigand, Cécile; Marchal, Frédéric; Classe, Jean‐Marc; Lorimier, G.; Chaisemartin, Cécile de; Guyon, Frédéric; Mariani, Pascale; Ortega‐Deballon, Pablo; Isaac, Sylvie; Maurice, C.; Gilly, François-Noël; Gléhen, Olivier; Avérous, Gerlinde; Bibeau, Frédéric; Bouzard, D.; Chevallier, A; Croce, Sabrina; Dartigues, Peggy; Durand-Fontanier, Sylvaine; Gouthi, L.; Heyd, Bruno; Kaci, Rachid; Kianmanesh, Réza; Laverrière, Marie‐Hélène; Leblanc, Éric; Lelong, Bernard; Leroux, Agnès; Loi, Valeria; Mariette, C.; Msika, Simon; Peyrat, Patrice; Pirrò, N.; Paineau, J; Poizat, Flora; Porcheron, J.; Rat, Patrick; Régimbeau, Jean‐Marc; Thibaudeau, Emilie; Tuech, Jean‐Jacques; Valmary‐Degano, Séverine; Verriele, Véronique; Zerbib, Philippe; Zinzindohoué, Franck

doi:10.1016/j.ejca.2016.06.002

Cited by 78 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of CRS‐HIPEC for the treatment of DMPM was reported before in only 13 pediatric cases, with favorable outcomes 3,5,33,37 . Our study confirms that CRS‐HIPEC could be used as first‐line treatment in children with resectable disease who are fit for major surgery 37‐39 . In our series, nine CRS‐HIPEC were performed in 11 patients with DMPM.…”

Section: Discussionsupporting

confidence: 81%

Multicystic and diffuse malignant peritoneal mesothelioma in children

Vermersch

Arnaud

Orbach

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Malignant and multicystic peritoneal mesotheliomas are extremely rare tumors in children, developing from mesothelial cells. No specific guidelines are available at this age. Methods: We performed a retrospective analysis of all identified children (< 18-year-old) treated in France from 1987 to 2017 for a diffuse malignant peritoneal mesothelioma (DMPM) or a multicystic peritoneal mesothelioma (MCPM). Results: Fourteen patients (5 males and nine females), aged 2.2 to 17.5 years, were included. The most frequent presenting symptoms were abdominal pain, ascitis, and alteration in the general condition. Eight patients had epithelioid mesothelioma, three had biphasic mesothelioma, and three had MCPM. Eight patients with DMPM diagnosis received cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Among them, six patients had neoadjuvant systemic chemotherapy, one patient, post-operative chemotherapy, and one patient CRS and HIPEC only. Three patients received only systemic chemotherapy. All patients with MCPM had only surgery. After a median follow-up of seven years (2-15), six patients (6/11; one death) with DMPM and two patients (two/three) with MCPM had a local and distant recurrences. Conclusion: Peritoneal mesothelioma in children is a rare condition with difficult diagnosis and high risk of recurrence. Worldwide interdisciplinary collaboration and networking are mandatory to help diagnosis and provide harmonious treatment guidelines.

show abstract

Section: Discussionsupporting

confidence: 81%

Multicystic and diffuse malignant peritoneal mesothelioma in children

Vermersch

Arnaud

Orbach

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Systemic therapy is usually reserved for patients who are not operative candidates for CRS and HIPEC. The benefit of systemic chemotherapy in a neoadjuvant or adjuvant setting around CRS and HIPEC has not been established . In general, the use of chemotherapy before or after a planned CRS and HIPEC procedure should be individualized and reserved for those who may not be medically optimized for immediate operative intervention or whose histopathology indicates a very high risk for early recurrence and progression.…”

Section: Treatmentmentioning

confidence: 99%

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone

Adusumilli

Alexander

et al. 2019

CA A Cancer J Clinicians

362

488

View full text Add to dashboard Cite

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment. CA Cancer J Clin 2019;69:402-429.

show abstract

“…The role of systemic chemotherapy in the neoadjuvant and adjuvant settings has not been fully examined. A retrospective multicenter study of 126 patients treated from 1991 to 2014 found an inferior 5‐year survival for neoadjuvant chemotherapy compared with adjuvant chemotherapy (40% vs 67%) 18 . Selection bias is a confounder because patients with more aggressive or bulkier disease are more likely to receive systemic therapy before surgery.…”

Section: Principles Of Chemotherapymentioning

confidence: 99%

The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma

Schuitevoerder¹,

Izquierdo²,

Plana³

et al. 2020

Cancer

View full text Add to dashboard Cite

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal mesothelioma. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.

show abstract

Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database

Cited by 78 publications

References 40 publications

Multicystic and diffuse malignant peritoneal mesothelioma in children

Multicystic and diffuse malignant peritoneal mesothelioma in children

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma

Contact Info

Product

Resources

About